文献速递泌尿生殖MRUS

栖息地风险评分通过及时识别进展改善前列腺癌主动监测

HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression.
PubMed 文献 · Acad Radiol · 2024-12-17

本研究在前瞻性主动监测临床试验MAST(NCT02242773)中评估栖息地风险评分(HRS)对早期识别进展者的作用。34例患者中15例为MRI/HRS进展者,19例为漏诊进展者(12例PI-RADS漏诊、7例穿刺漏诊);HRS在所有病例中确认了PI-RADS评估,并在PI-RADS漏诊组中识别出所有未被穿刺靶向的病灶并使患者重新分类。HRS体积与肿瘤体积和侵袭性随时间演变明显相关。

要点

  • HRS在所有病例中确认了PI-RADS评估,可作为mpMRI自动分析工具辅助判读。
  • PI-RADS漏诊组中HRS识别出所有未被穿刺靶向的病灶,并导致患者重新分类。
  • HRS体积与肿瘤体积及侵袭性随时间演变明显相关,可能作为早期检测进展的定量生物标志物。

核心结论

  • HRS体积可作为早期检测进展的定量生物标志物,有助于及时转换为治疗,从而改善患者结局并减少不必要监测的负担。

研究设计与样本

  • 前瞻性主动监测临床试验MAST(NCT02242773)分析,纳入34例患者,方案包括确诊性mpMRI-超声融合穿刺及每年监测性MRI-超声融合穿刺至多3年。

关键影像表现/征象

  • HRS在所有病例中确认了PI-RADS评估。
  • PI-RADS漏诊组中HRS识别出所有未被穿刺靶向的病灶并使患者重新分类。
  • HRS体积与肿瘤体积和侵袭性随时间的演变明显相关。

诊断标准与关键数值

  • 进展者分为MRI/HRS进展者(PI-RADS病灶在监测全程被靶向且穿刺阳性)和漏诊进展者(PI-RADS漏诊或穿刺漏诊)。
  • 34例患者中15例为MRI/HRS进展者,19例为漏诊进展者(12例PI-RADS漏诊、7例穿刺漏诊)。

临床应用与阅片要点

  • HRS可辅助mpMRI判读,在PI-RADS漏诊时识别未被靶向的病灶并提示重新分类。
  • HRS体积变化可作为监测中肿瘤体积和侵袭性演变的定量参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Active surveillance (AS) is the preferred management strategy for low-risk prostate cancer. This study aimed to evaluate the impact of Habitat Risk Score (HRS), an automated approach for mpMRI analysis, for early detection of progressors in a prospective AS clinical trial (MAST NCT02242773).

MATERIALS AND METHODS: The MAST protocol includes Confirmatory mpMRI ultrasound fusion (MRI-US) biopsy and yearly surveillance MRI-US biopsies for up to 3 years. Clinical and mpMRI data from patients that progressed based on protocol criteria at years 1-3 were reviewed. Patients were classified as "MRI/HRS Progressors" if the PI-RADS lesion(s) had been targeted throughout the surveillance and resulted in positive biopsies, or as "Missed Progressors" if the lesion(s) were not identified by PI-RADS ("PI-RADS Miss") or were missed by the biopsy ("Needle Miss"). HRS maps were generated for each patient and evaluated for association with histopathological progression.

RESULTS: Of the 34 patients, 15 were classified as "MRI/HRS Progressors" and 19 as "Missed Progressors" (12 "PI-RADS Miss", seven "Needle Miss"). In all cases, HRS confirmed the PI-RADS assessment. In the "PI-RADS Miss" group, HRS identified the lesions in all patients that were not targeted by biopsy and resulted in patient reclassification. HRS volumes showed clear association with tumor evolution both in terms of volume and aggressiveness over time.

CONCLUSION: HRS volumes can serve as a quantitative biomarker for early detection of progression and lead to timely conversion to treatment, thereby improving patient outcomes and reducing the burden of unnecessary surveillance.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Kimbel IM, Wallaengen V, Zacharaki EI, et al. HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression. Acad Radiol. 2024. PMID: 39694787. doi:10.1016/j.acra.2024.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。